Search results :

ICI 182,780

More information: STITCH, PubChem and possibly Wikipedia

ATC Code: L02BA03

Side effects

Options: Hide MedDRA Preferred Terms

MedDRA Preferred Term Side effect Data for drug Placebo Labels
1 2 3
Asthenia Asthenia postmarketing, 5.82% - 27% x x x
Fatigue 6.42% - 7.48% x
Nausea Nausea postmarketing, 9.7% - 26% x x x
Pain Pain postmarketing, 18.9% - 20.3% x x
Malnutrition Malnutrition 17.7% - 18.2% x x x
Vasodilation procedure Vasodilation postmarketing, 17.3% - 17.7% x
Headache Headache postmarketing, 6.68% - 16.8% x x x
Pharyngitis Pharyngitis 11.6% - 16.1% x x
Bone pain Bone pain 7.49% - 15.8% x x
Back pain Back pain 7.48% - 14.4% x x x
Diarrhoea Diarrhoea postmarketing, 12.3% - 12.8% x x x
Dyspnoea Dyspnoea 4.43% - 14.9% x x
Vomiting Vomiting postmarketing, 5.61% - 13% x x x
Abdominal pain Abdominal pain 11.6% - 11.8% x x
Gastrointestinal pain Abdominal pain 11.6% - 11.8% x x
Constipation Constipation 3.48% - 12.5% x x
Cough Cough increased 10.4% x x
Cough 5.26% - 5.35% x
Injection site pain Injection site pain 6.6% - 11.6% x x
Oedema peripheral Oedema peripheral 9% - 10.2% x x
Pelvic pain Pelvic pain 9% - 9.9% x x
Decreased appetite Anorexia postmarketing, 3.74% - 10.9% x x x
Arthralgia Arthralgia 7.75% - 8.03% x
Musculoskeletal discomfort Arthralgia 7.75% - 8.03% x
Myalgia postmarketing x
Insomnia Insomnia 6.9% - 8.5% x x
Dermatitis Rash postmarketing, 7.3% - 8% x x x
Rash Rash postmarketing, 7.3% - 8% x x x
Paraesthesia Paraesthesia 6.4% - 7.6% x x
Fatigue Fatigue 6.42% - 7.48% x
Pain in extremity Pain in extremity 6.93% - 6.95% x
Dizziness Dizziness 6.6% - 6.9% x x
Influenza Influenza 6.4% - 7.1% x x
Body temperature increased Body temperature increased 6.4% x x
Depression Depression 5.7% - 6.9% x x
Chest pain Chest pain 5% - 7.1% x x
Hyperhidrosis Sweating 5% - 5.2% x x
Injury Accidental injury 4.5% - 5.7% x x
Anaemia Anaemia 4.5% - 5% x x
Arthritis Arthritis 2.8% - 6.1% x x
Anxiety Anxiety 3.8% - 5% x x
Musculoskeletal pain Musculoskeletal pain 3.21% - 5.54% x
Urinary tract infection Urinary tract infection postmarketing, 3.5% - 6.1% x x x
Menopausal symptoms Hot flush postmarketing, 5.88% - 6.65% x x x
Hot flush Hot flush postmarketing, 5.88% - 6.65% x x x
Angioedema Angioedema postmarketing x x
Haemorrhage Haemorrhage postmarketing x
Haemoglobin Haemorrhage postmarketing x
Hepatitis Hepatitis postmarketing x
Hypersensitivity Hypersensitivity postmarketing x x x
Inflammation Inflammation postmarketing x x
Leukopenia Leukopenia postmarketing x
Pruritus Pruritus postmarketing x
Urticaria Urticaria postmarketing x x
Vertigo Vertigo postmarketing x
Hepatic failure Hepatic failure postmarketing x x
Injection site reaction Injection site reaction postmarketing x x x
Myalgia Myalgia postmarketing x
Dyspepsia Digestion impaired postmarketing x
Gastrointestinal disorder Digestion impaired postmarketing x
Gastrointestinal disorder x
Gastrointestinal symptom NOS x
Hepatic enzyme increased Hepatic enzyme increased postmarketing x
Breast cancer stage IV Breast cancer stage IV postmarketing x
Vaginal haemorrhage Vaginal haemorrhage postmarketing x x
Breast disorder Breast disorder x
Vulvovaginal candidiasis Vaginal moniliasis x
Vulvovaginal mycotic infection Vaginal moniliasis x
Infection Infection x
Connective tissue disorder Connective tissue disorder x
Hepatitis C Hepatitis C x
Immune system disorder Immune system disorder x
Vaginal discharge Leukorrhea x
Nervous system disorder Nervous system disorder x
Angiopathy Angiopathy x
Gamma-glutamyltransferase increased Gamma-glutamyltransferase increased x
Injection site haemorrhage Injection site haemorrhage x
Skin disorder Unspecified disorder of skin and subcutaneous tissue x
Hepatobiliary disease Hepatobiliary disease x
Blood bilirubin increased Blood bilirubin increased x
Injection site haematoma Injection site haematoma x
Infestation Infestation NOS x
Embolism venous Venous thromboembolism x

Indications

Information about indications was extracted from the indications and usage sections of the labels.

fulvestrant / fulvestrant

Side effects:33
Source:EMA

FULVESTRANT / FASLODEX

Side effects:43
Source:Health Canada

FULVESTRANT

Side effects:51
Source:FDA Structured Product Label

Color scheme:

standard – alternative

    100%
    75%
    50%
    10%
    frequent (1% to 100%)
    infrequent (0.1% to 1%)
    rare (<0.1%)
    postmarketing
    0%
    no frequency information
    not found on label